Filtered By:
Condition: Disability
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 65 results found since Jan 2013.

A Young Woman with Ischemic Stroke: Should We Pay More Attention to Varicella Zoster Infection?
In conclusion, VZV vasculopathy needs to be considered in young adults with stroke. A high index of suspicion and early treatment seem to be important to minimize morbidity and mortality. Anticoagulation should probably be avoided in stroke associated with VZV vasculopathy.Case Rep Neurol 2016;8:145–150
Source: Case Reports in Neurology - July 7, 2016 Category: Neurology Source Type: research

Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
Stroke is one of the world's leading causes of disability and death. Antiplatelet agents are administered to acute ischemic stroke patients as secondary prevention. Clopidogrel involves biotransformation by cytochrome P450 (CYP) enzymes into an active metabolite, and single nucleotide polymorphisms (SNPs) can influence the efficacy of this biotransformation. Despite the therapeutic advantages of aspirin, there is significant inter-individual heterogeneity in response to this antiplatelet drug. In this clinical review, the recent advances in the biomarkers of antiplatelet agents in acute ischemic stroke are discussed. The s...
Source: Frontiers in Neurology - June 10, 2021 Category: Neurology Source Type: research

Human placenta mesenchymal stem cell protection in ischemic stroke is angiotensin converting enzyme ‐2 and masR receptor‐dependent
Angiotensin converting enzyme-2 (ACE-2) contributes to human placenta mesenchymal stem cell (hPMSC)-induced protection against ischemic injury through MasR pathway. AbstractThromboembolic stroke remains a major cause of neurological disability and death. Current stroke treatments (aspirin, tissue plasminogen activator) are significantly limited by timing and risks for hemorrhage which have driven researchers to explore other approaches. Stem cell-based therapy appears to be an effective option for ischemic stroke. Besides trans-differentiation into neural cells, stem cells also provide acute protection via paracrine signal...
Source: Stem Cells - June 22, 2021 Category: Stem Cells Authors: Mansoureh Barzegar, Shantel Vital, Karen Y. Stokes, Yuping Wang, Jungmi Winny Yun, Luke A. White, Oleg Chernyshev, Roger E. Kelley, Jonathan S. Alexander Tags: Regenerative Medicine Source Type: research

Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence
Semin Neurol 2017; 37: 366-375 DOI: 10.1055/s-0037-1603469Acute stroke is a leading cause of death and disability in the developed world. Among survivors, the risk of stroke recurrence is highest within the first few days, and up to 15% will be affected within the first year. In the case of noncardioembolism, antiplatelets, such as aspirin, clopidogrel, and the combination of aspirin and dipyridamole, remain the mainstay of treatment. Aspirin given immediately is beneficial, but when combined with clopidogrel is associated with a higher risk of bleeding. Dual antiplatelet therapy of aspirin and dipyridamole was no more eff...
Source: Seminars in Neurology - July 31, 2017 Category: Neurology Authors: Krishnan, Kailash Jusufovic, Mirza Sandset, Per Morten Sandset, Else Charlotte Tags: Review Article Source Type: research

Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond: Medical and Ethical Issues
AbstractPurpose of reviewAs one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group.Recent findingsSeveral recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for t...
Source: Current Treatment Options in Neurology - May 7, 2019 Category: Neurology Source Type: research

E-176 Endovascular stent retriever thrombectomy of medium and small vessel occlusion of the middle cerebral artery with acute ischemic stroke: a case series
ConclusionsOur case series demonstrated that SRMT in SVO with disabling NIHSS is feasible and safe if performed carefully. All patient achieved TICI 3 perfusion and first pass effect was better observed in trap technique and use of long solitaire STD. Good function outcomes were achieved in all cases irrespective of the types of SRD used and passes required to achieve TICI 3 perfusion. Further studies are required.Disclosures Y. Lodi: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lodi, Y. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

Million hearts: prevalence of leading cardiovascular disease risk factors - United States, 2005-2012.
Abstract Each year, approximately 1.5 million U.S. adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability. Overall, an estimated 14 million survivors of heart attacks and strokes are living in the United States. In 2011, the U.S. Department of Health and Human Services, in collaboration with nonprofit and private organizations, launched Million Hearts (http://www.millionhearts.hhs.gov), an initiative focused on implementing clinical and community-level evidence-based strategies to reduce cardiovascular disease (CVD) risk...
Source: MMWR Morb Mortal Wkl... - May 30, 2014 Category: Epidemiology Authors: Ritchey MD, Wall HK, Gillespie C, George MG, Jamal A, Division for Heart Disease and Stroke Prevention, CDC Tags: MMWR Morb Mortal Wkly Rep Source Type: research

Taking aspirin quickly after minor stroke 'can cut risk of recurrence'
Urgent treatment with blood-thinning drug greatly reduces risk of subsequent fatal or disabling stroke, research findsDeath and disability can be averted by quickly taking aspirin after a minor stroke, a study has found. The blood-thinning drug is already given to people who have suffered a transient ischaemic attack (TIA), or “mini-stroke”, after they have been assessed in hospital. Continue reading...
Source: Guardian Unlimited Science - May 19, 2016 Category: Science Authors: Press Association Tags: Medical research Aspirin UK news Science Health Source Type: news

Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
ConclusionsBased on the present analysis, apixaban represents a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with AF from a Greek healthcare payer perspective over a lifetime horizon.
Source: American Journal of Cardiovascular Drugs - November 22, 2016 Category: Cardiology Source Type: research

Alteplase for acute ischemic stroke after heparin reversal with protamine – a case report and review
ConclusionsGiven the lack of adverse events associated with IV alteplase in our patient, we advocate cautious evaluation for potential reversal of acutely administered anticoagulation to facilitate alteplase administration in severely disabled patients who are not eligible for mechanical intervention, and who would have been excluded from definitive AIS treatment.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 25, 2017 Category: Drugs & Pharmacology Authors: Gabriel V. Fontaine, Shawn M. Smith Tags: Case Report Source Type: research

Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review
We describe the first reported case of a patient receiving full‐dose intravenous (IV) alteplase for AIS after heparin reversal with protamine. A 73‐year‐old man presented with AIS. He was treated with IV heparin, tirofiban, loading‐dose prasugrel, and aspirin before percutaneous coronary intervention (PCI) for placement of a right coronary artery stent. One hour following PCI, he abruptly developed left hemiparesis and dysphagia. The National Institutes of Health Stroke Scale was 12, and activated partial thromboplastin time (aPTT) was longer than 150 seconds. Head computed tomography (CT) showed no acute patholog...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - September 4, 2017 Category: Drugs & Pharmacology Authors: Gabriel V. Fontaine, Shawn M. Smith Tags: Case Report Source Type: research

Pre-treatment of Single and Double Antiplatelet and Anticoagulant With Intravenous Thrombolysis for Older Adults With Acute Ischemic Stroke: The TTT-AIS Experience
Conclusion: For older adults with higher baseline severity of acute ischemic stroke, DAPP may increase the risk of SICH and mortality post IVT. However, DAPP is still not an indication to withdraw IVT and to prescribe low-dose IVT for older adults.
Source: Frontiers in Neurology - February 22, 2021 Category: Neurology Source Type: research

Risk of aspirin-related bleeding is higher in the over-75s
Conclusion This valuable cohort study helps to quantify the extent of bleeding risk in people taking aspirin for secondary prevention of cardiovascular disease. Aspirin is well known to carry bleeding risk – particularly in older adults – but this study suggests the risk may be higher than previously thought. The researchers say that for adults under the age of 75, the annual bleeding risk at around 1% is similar to that suggested by previous trials, as is the ratio of bleeds to the number of cardiovascular events. However, this risk increases for older adults, especially for major bleeds of the stomach and upper diges...
Source: NHS News Feed - June 14, 2017 Category: Consumer Health News Tags: Medication Older people Source Type: news

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Cilostazol for treatment of cerebral infarction.
Authors: Noma K, Higashi Y Abstract INTRODUCTION: Stroke not only causes critical disability and death but is also a cause of anxiety with the possibility of secondary cardiovascular events including secondary ischemic stroke. Indeed, patients with a history of previous stroke have a high rate of stroke recurrence, indicating the clinical importance of secondary stroke prevention. Area of covered: This review provides an overview of the pooled evidence for cilostazol's use in the management of secondary stroke prevention. Among the various antiplatelet agents that are available, aspirin is the most frequently used ...
Source: Expert Opinion on Pharmacotherapy - September 14, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research